The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Sep. 30, 2016
Applicant:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Inventors:

John Robert Pollard, Abingdon, GB;

Peter Littlewood, Abingdon, GB;

Philip Michael Reaper, Abingdon, GB;

Mohammed Asmal, Newton, MA (US);

Scott Zachary Fields, Towaco, NJ (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 31/7068 (2006.01); A61K 31/4965 (2006.01); A61K 31/555 (2006.01); A61K 31/519 (2006.01); A61K 31/282 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/497 (2013.01); A61K 31/282 (2013.01); A61K 31/4965 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01);
Abstract

Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.


Find Patent Forward Citations

Loading…